Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge.
Animals
Antiviral Agents
/ pharmacology
Chlorocebus aethiops
Disease Models, Animal
Drug Evaluation, Preclinical
Female
HEK293 Cells
HeLa Cells
Henipavirus Infections
/ drug therapy
Humans
Mesocricetus
Nipah Virus
/ drug effects
Plant Lectins
/ pharmacology
Vero Cells
Virus Internalization
/ drug effects
Griffithsin
Nipah
antiviral
hamster
therapeutic
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
11 May 2020
11 May 2020
Historique:
pubmed:
11
2
2020
medline:
25
6
2020
entrez:
11
2
2020
Statut:
ppublish
Résumé
Nipah virus (NiV) is a highly pathogenic zoonotic paramyxovirus that causes fatal encephalitis and respiratory disease in humans. There is currently no approved therapeutic for human use against NiV infection. Griffithsin (GRFT) is high-mannose oligosaccharide binding lectin that has shown in vivo broad-spectrum activity against viruses, including severe acute respiratory syndrome coronavirus, human immunodeficiency virus 1, hepatitis C virus, and Japanese encephalitis virus. In this study, we evaluated the in vitro antiviral activities of GRFT and its synthetic trimeric tandemer (3mG) against NiV and other viruses from 4 virus families. The 3mG had comparatively greater potency than GRFT against NiV due to its enhanced ability to block NiV glycoprotein-induced syncytia formation. Our initial in vivo prophylactic evaluation of an oxidation-resistant GRFT (Q-GRFT) showed significant protection against lethal NiV challenge in Syrian golden hamsters. Our results warrant further development of Q-GRFT and 3mG as potential NiV therapeutics.
Identifiants
pubmed: 32037447
pii: 5731546
doi: 10.1093/infdis/jiz630
pmc: PMC7199786
doi:
Substances chimiques
Antiviral Agents
0
Plant Lectins
0
griffithsin protein, Griffithsia
Z8PX5UX50U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S480-S492Subventions
Organisme : NIAID NIH HHS
ID : U19 AI113182
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Références
Viruses. 2016 Nov 17;8(11):
pubmed: 27869695
PLoS Pathog. 2010 Jul 15;6(7):e1000993
pubmed: 20657665
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6099-104
pubmed: 19332801
PLoS Pathog. 2013;9(10):e1003684
pubmed: 24130486
Sci Rep. 2016 Aug 03;6:30916
pubmed: 27484128
Sci Rep. 2018 May 15;8(1):7604
pubmed: 29765101
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
J Biol Chem. 2005 Mar 11;280(10):9345-53
pubmed: 15613479
Antimicrob Agents Chemother. 2013 Aug;57(8):3976-89
pubmed: 23752505
Sci Rep. 2017 Mar 08;7:43610
pubmed: 28344321
Antimicrob Agents Chemother. 2014;58(1):120-7
pubmed: 24145548
J Virol. 2010 Mar;84(5):2511-21
pubmed: 20032190
Retrovirology. 2015 Jan 23;12:6
pubmed: 25613831
Antiviral Res. 2017 Aug;144:147-152
pubmed: 28629988
Virology. 2011 Aug 15;417(1):126-36
pubmed: 21676427
Viruses. 2016 Dec 17;8(12):
pubmed: 27999325
mBio. 2015 Mar 10;6(2):e02427
pubmed: 25759505
J Virol. 2015 Mar;89(5):2520-9
pubmed: 25505064
J Virol. 2005 Jan;79(2):1113-24
pubmed: 15613339
J Virol. 1999 Jan;73(1):251-9
pubmed: 9847328
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
J Virol. 2011 Mar;85(5):2004-11
pubmed: 21177820
Structure. 2010 Sep 8;18(9):1104-15
pubmed: 20826337
PLoS One. 2013 May 21;8(5):e64449
pubmed: 23700478
Antiviral Res. 2017 Nov;147:91-99
pubmed: 29024765
J Immunol. 2005 Jul 1;175(1):413-20
pubmed: 15972675
Emerg Infect Dis. 2012 Feb;18(2):248-55
pubmed: 22304936
Protein Sci. 2007 Jul;16(7):1485-9
pubmed: 17567736
Virology. 2004 Apr 10;321(2):247-59
pubmed: 15051385
PLoS One. 2011;6(8):e22635
pubmed: 21829638
PLoS Pathog. 2014 Mar 13;10(3):e1004001
pubmed: 24626480
Virol J. 2005 Jul 18;2:57
pubmed: 16026621
J Infect Dis. 2019 May 24;219(12):1855-1857
pubmed: 30365002
Virol J. 2010 Jun 03;7:115
pubmed: 20525276
Antiviral Res. 2015 Aug;120:40-7
pubmed: 25986249
Antiviral Res. 2014 Jun;106:53-60
pubmed: 24680955
J Virol. 2012 Nov;86(22):11991-2002
pubmed: 22915812
Adv Biosci Biotechnol. 2011 Dec;2(6):404-408
pubmed: 22611520
J Infect Dis. 2018 Jun 20;218(2):218-227
pubmed: 29566184
Proteins. 2007 May 15;67(3):661-70
pubmed: 17340634
J Med Chem. 2009 Jul 23;52(14):4257-65
pubmed: 19499921
J Virol. 2015 Feb;89(4):2192-200
pubmed: 25473055
Arch Virol. 2013 Feb;158(2):349-58
pubmed: 23053519
J Virol. 2006 May;80(10):4878-89
pubmed: 16641279
Antiviral Res. 2016 Dec;136:9-18
pubmed: 27771389
BMC Biotechnol. 2015 Feb 22;15:12
pubmed: 25887919